Chief Business Officer, Cage Therapeutics
Dr. William Shen is currently the Chief Business Officer at Cage Therapeutics, part of 4:59 Initiative at 5AM Ventures. Previously, Dr. Shen was the CBO at Orna Therapeutics, a leading company developing circular RNA-based therapeutics. At Orna, he led the negotiation and execution of a landmark collaboration between Merck and Orna in 2022. Prior to Orna, Dr. Shen was the Head of Corporate Development at Biogen, overseeing M&A, BD&L, Strategy, and Alliance Management. Under his leadership, Biogen completed more than 15 business development transactions in 2020, including partnerships with Denali and Sage, two of the largest transactions in Neuroscience that year. Prior to Biogen, Dr. Shen was an M&A Lead at BMS. Before joining the industry as a business development executive, Dr. Shen was a venture investor at venBio and Johnson & Johnson Development Corporation.
Dr. Shen obtained his PhD in Chemical Engineering at Stanford as an NSF and NIH Fellow, a BS in Chemistry from the University of Florida, and an MBA from the Wharton School at the University of Pennsylvania.
